ANTHONY MONTOYA

Advocated for amending testing language in Section 3201 of the CARES Act to clarify responsibility for diagnostic testing related to COVID-19. Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; benchmark reform, and program integrity audits. Advocated for legislation suspending the Medicare sequester through December 31, 2021 including H.R. 1868, "To prevent across-the-board direct spending cuts, and for other purposes." and H.R.315, the "Medicare Sequester COVID Moratorium Act." Advocated for increased Medicaid funding during the Public Health Emergency. Advocated for access to CDCs data lake to determine whether a patient has received a COVID-19 vaccination, which vaccine they received, and when they will need to receive a second dose. Advocated for allowing MA organizations to use a 24-month look-back period to supplement 2020 data for the calculation of 2021 risk scores. Telehealth - Allow more clinicians to provide virtual care, ensure all telehealth encounters, including audio-only, are eligible for risk adjustment. Audio-only advocacy included on H.R. 2166, To amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs, and for other purposes. and S.150, the Ensuring Parity in MA for Audio-Only Telehealth Act of 2021

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; benchmark reform, and program integrity audits. Advocated for access to CDCs data lake to determine whether a patient has received a COVID-19 vaccination, which vaccine they received, and when they will need to receive a second dose. Advocated for allowing MA organizations to use a 24-month look-back period to supplement 2020 data for the calculation of 2021 risk scores. Telehealth - Allow more clinicians to provide virtual care, ensure all telehealth encounters, including audio-only, are eligible for risk adjustment. Audio-only advocacy included on H.R. 2166, S.150, the Ensuring Parity in MA for Audio-Only Telehealth Act of 2021

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012) Legislation related to the COVID-19 Public Health Emergency - the Paycheck Protection Program and Health Care Enhancement Act (H.R. 266, "Phase 3.5") and the Health and Economic Recovery Omnibus Emergency Solutions Act (H.R.6800, the "HEROES" Act). Issues included premium support for small businesses, establishing a federal reinsurance pool, risk corridors for the health insurance exchanges, the Health Coverage Tax Credits program, COBRA subsidies, opening a special enrollment period for federal exchanges. Lobbied Administration regarding further guidance and public funding for COVID-19 testing. Advocated for making COVID-19 related telehealth regulatory flexibilities permanent. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan comparison tool. Advocated for delaying the interoperability final rule compliance deadlines.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality bonus payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, and suspending the Medicare sequester.

Advocated for amending testing language in Section 3201 of the CARES Act to clarify responsibility for diagnostic testing related to COVID-19. Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for suspending the Medicare sequester for Rural Hospitals, other providers, and health plans. Advocated for access to CDCs data lake to determine whether a patient has received a COVID-19 vaccination, which vaccine they received, and when they will need to receive a second dose. Advocated for allowing MA organizations to use a 24-month look-back period to supplement 2020 data for the calculation of 2021 risk scores.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, suspending Medicare sequester, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated for additional guidance about financial responsibility for COVID-19 testing and additional public funding for COVID-19 testing.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated for additional guidance about financial responsibility for COVID-19 testing and additional public funding for COVID-19 testing. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for rural health issues including suspending the Medicare sequester for Rural Hospitals, other providers, and health plans for 5 years.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012) Legislation related to the COVID-19 Public Health Emergency - the Paycheck Protection Program and Health Care Enhancement Act (H.R. 266, "Phase 3.5") and the Health and Economic Recovery Omnibus Emergency Solutions Act (H.R.6800, the "HEROES" Act). Issues included premium support for small businesses, establishing a federal reinsurance pool, risk corridors for the health insurance exchanges, the Health Coverage Tax Credits program, COBRA subsidies, opening a special enrollment period for federal exchanges. Lobbied Administration regarding further guidance and public funding for COVID-19 testing. Advocated for making COVID-19 related telehealth regulatory flexibilities permanent. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan comparison tool. Advocated for delaying the interoperability final rule compliance deadlines.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012) Legislation related to the COVID-19 Public Health Emergency - the Paycheck Protection Program and Health Care Enhancement Act (H.R. 266, "Phase 3.5") and the Health and Economic Recovery Omnibus Emergency Solutions Act (H.R.6800, the "HEROES" Act). Issues included premium support for small businesses, establishing a federal reinsurance pool, risk corridors for the health insurance exchanges, the Health Coverage Tax Credits program, COBRA subsidies, opening a special enrollment period for federal exchanges. Lobbied Administration regarding further guidance and public funding for COVID-19 testing. Advocated for making COVID-19 related telehealth regulatory flexibilities permanent. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan comparison tool. Advocated for delaying the interoperability final rule compliance deadlines.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated for additional guidance about financial responsibility for COVID-19 testing and additional public funding for COVID-19 testing. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for rural health issues including suspending the Medicare sequester for Rural Hospitals, other providers, and health plans for 5 years.

Advocated for amending testing language in Section 3201 of the CARES Act to clarify responsibility for diagnostic testing related to COVID-19. Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for suspending the Medicare sequester for Rural Hospitals, other providers, and health plans. Advocated for access to CDCs data lake to determine whether a patient has received a COVID-19 vaccination, which vaccine they received, and when they will need to receive a second dose. Advocated for allowing MA organizations to use a 24-month look-back period to supplement 2020 data for the calculation of 2021 risk scores.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012) Legislation related to the COVID-19 Public Health Emergency - the Paycheck Protection Program and Health Care Enhancement Act (H.R. 266, "Phase 3.5") and the Health and Economic Recovery Omnibus Emergency Solutions Act (H.R.6800, the "HEROES" Act). Issues included premium support for small businesses, establishing a federal reinsurance pool, risk corridors for the health insurance exchanges, the Health Coverage Tax Credits program, COBRA subsidies, opening a special enrollment period for federal exchanges. Lobbied Administration regarding further guidance and public funding for COVID-19 testing. Advocated for making COVID-19 related telehealth regulatory flexibilities permanent. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan comparison tool. Advocated for delaying the interoperability final rule compliance deadlines.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality bonus payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, and suspending the Medicare sequester.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, suspending Medicare sequester, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated for additional guidance about financial responsibility for COVID-19 testing and additional public funding for COVID-19 testing.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated for additional guidance about financial responsibility for COVID-19 testing and additional public funding for COVID-19 testing. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for rural health issues including suspending the Medicare sequester for Rural Hospitals, other providers, and health plans for 5 years.

Advocated for amending testing language in Section 3201 of the CARES Act to clarify responsibility for diagnostic testing related to COVID-19. Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; quality bonus payments; prescription drug costs; and program integrity audits. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency - Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, establishing a Medicaid Stabilization Fund. Advocated for making telehealth regulatory flexibilities during the COVID-19 Public Health Emergency permanent. Advocated to allow audio-only telehealth services for risk adjustment in Medicare Advantage plans, including support for H.R. 7659, the "Ensuring Parity in MA for Audio-Only Telehealth Act of 2020." Advocated for suspending the Medicare sequester for Rural Hospitals, other providers, and health plans. Advocated for access to CDCs data lake to determine whether a patient has received a COVID-19 vaccination, which vaccine they received, and when they will need to receive a second dose. Advocated for allowing MA organizations to use a 24-month look-back period to supplement 2020 data for the calculation of 2021 risk scores.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality bonus payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included risk corridors for Medicare Advantage, maintaining payment parity between Medicare Advantage and traditional fee-for-service Medicare, and suspending the Medicare sequester.

HIPAA and 42 CFR Part 2 patient confidentiality reforms (H.R.2062/S.1012); H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391); the SPIKE Act (H.R.2069); Second Look at Drug Patents Act (S.1617); and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Legislation related to the COVID-19 Public Health Emergency: S.3548, the Coronavirus Aid, Relief and Economic Security (CARES) Act. Issues included premium support for small businesses, establishing a federal reinsurance pool, and risk corridors for the health insurance exchanges. Advocated for immediately opening a special enrollment period for the health insurance exchanges and for delay of health data interoperability final rule deadlines until at least January 1, 2022. Advocated for more prominent display of quality metrics on the Federal Employee Health Benefits Program plan finder.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS staff regarding health data interoperability.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; surprise billing; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS and OMB staff regarding health data innovation, and SAMHSA regarding 42 CFR Part 2 reform.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; surprise billing; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS and OMB staff regarding health data innovation, and SAMHSA regarding 42 CFR Part 2 reform.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS staff regarding health data interoperability.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS staff regarding health data interoperability.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; surprise billing; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS and OMB staff regarding health data innovation, and SAMHSA regarding 42 CFR Part 2 reform.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and ratings systems; quality incentive payments; and prescription drug costs. Medicare Advantage Quality Payments, including H.R.2131 the "Medicare Advantage Quality Payment Relief Act," corresponding Senate bill is S.1114. H.R.3, the "Lower Drug Costs Now Act," including the Part D restructuring components of the bill.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; surprise billing; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS and OMB staff regarding health data innovation, and SAMHSA regarding 42 CFR Part 2 reform.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS staff regarding health data interoperability.

Legislation pertaining to the Patient Protection and Affordable Care Act; stability of the individual market; tax credits and cost-sharing reduction subsidies; insurer taxes; affordability; HIPAA and 42CFR Part 2 patient confidentiality reforms; surprise billing; H.R.3, the "Lower Drug Costs Now Act of 2019," all sections of the bill, and "The Lower Health Care Costs Act", S. 1895. Drug pricing legislation including the CREATES act (H.R.965); the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499); FAIR drug pricing act (S.1391) and legislation/language incentivizing transparent pharmacy benefit managers (PBMs). Met with HHS and OMB staff regarding health data innovation, and SAMHSA regarding 42 CFR Part 2 reform.